Pulmonx Corp Stock Price, News & Analysis

Pulmonx (Nasdaq: LUNG), a leader in minimally invasive treatments for severe lung disease, has announced its participation in the Piper Sandler 36th Annual Healthcare Conference. The company will engage in a fireside chat on Wednesday, December 4, 2024, at 9:30 AM PT / 12:30 PM ET in New York. Interested parties can access both live and archived webcasts of the presentation through the 'Investors' section of the Pulmonx website.

Pulmonx (Nasdaq: LUNG) and the American Lung Association are expanding their partnership with two new educational initiatives for severe COPD and emphysema patients. The programs include patient stories on the EACH BREATH blog in November 2024 featuring experiences with endobronchial valve (EBV) treatment, and an 'Ask the Expert' Q&A session with a pulmonologist in January on the Lung Association's online communities. The collaboration aims to increase awareness about Zephyr® Endobronchial Valve therapy and provide educational resources for patients and healthcare providers dealing with COPD, which remains the third leading cause of death worldwide according to WHO.

Pulmonx (Nasdaq: LUNG), a leader in minimally invasive treatments for severe lung disease, has announced its participation in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum. The company will engage in investor meetings at the event, which is scheduled to take place in New York on Thursday, November 21, 2024.

Pulmonx (Nasdaq: LUNG), a leader in minimally invasive treatments for severe lung disease, has announced its participation in the Stifel 2024 Healthcare Conference. The company will engage in a fireside chat on Tuesday, November 19, 2024, at 6:10 AM PT / 9:10 AM ET in New York.

Interested parties can access both live and archived webcasts of the presentation through the 'Investors' section of the Pulmonx website at https://investors.pulmonx.com/.

Pulmonx (LUNG) reported Q3 2024 financial results with worldwide revenue of $20.4 million, up 15% year-over-year. U.S. revenue grew 17% to $13.8 million, while international revenue increased 12% to $6.6 million. The company maintained a gross margin of 74% and reported a net loss of $14.1 million ($0.36 per share). Operating expenses increased 3% to $29.2 million. The company added 15 new Zephyr Valve treatment centers and maintains its full-year 2024 revenue guidance of $81-84 million with expected gross margin of 74%.

Pulmonx (Nasdaq: LUNG), a global leader in minimally invasive treatments for lung disease, has announced that it will release its third quarter 2024 financial results after the close of trading on Wednesday, October 30, 2024. The company management will host a conference call to discuss the financial results, starting at 1:30 p.m. PT / 4:30 p.m. ET on the same day.

Investors and interested parties can access a live and archived webcast of the event on the 'Investors' section of the Pulmonx website at https://investors.pulmonx.com/. This announcement provides an opportunity for stakeholders to gain insights into the company's financial performance and future outlook.

Pulmonx (Nasdaq: LUNG) presented clinical data from two significant studies at the European Respiratory Society Congress 2024. The AeriSeal® CONVERT trial showed that 77.6% of patients with collateral ventilation (CV+) successfully converted to CV- status after treatment with the AeriSeal System, making them eligible for Zephyr® Valve treatment. These patients experienced improvements in lung function, quality of life, and treated lobe volume reduction.

The 5-year follow-up data from the LIBERATE study demonstrated durable improvements in lung function for patients treated with Zephyr Valves, with FEV1 improvements ranging from 109 mL in Year 1 to 79 mL at Year 5. The study also showed an acceptable safety profile and a 38% mortality rate over 5 years, lower than historical medically managed control patients.

Pulmonx (Nasdaq: LUNG), a global leader in minimally invasive treatments for severe lung disease, has announced its participation in the Lake Street 8th Annual Best Ideas Growth Conference. The event is scheduled to take place on Thursday, September 14, 2024, in New York.

Pulmonx representatives will be engaging in investor meetings during the conference, providing an opportunity for the company to showcase its innovations and growth strategies in the field of lung disease treatment. This participation underscores Pulmonx's commitment to engaging with investors and sharing insights about its market position and future prospects.

Pulmonx (Nasdaq: LUNG), a leader in minimally invasive treatments for severe lung disease, has announced its participation in the 2024 Wells Fargo Healthcare Conference in Boston. The company will engage in a fireside chat on Thursday, September 5, 2024, at 1:30 PM PT / 4:30 PM ET.

Investors and interested parties can access a live and archived webcast of the presentation through the 'Investors' section of the Pulmonx website at https://investors.pulmonx.com/. This event provides an opportunity for Pulmonx to showcase its innovations and discuss its position in the healthcare industry with potential investors and analysts.